Data from Phase 1b/2a study in chronic HBV patients show robust HBV specific T cell responses in ≥ 50% of evaluable patients across all study arms of VBI-2601 (BRII-179)
VBI-2601 (BRII-179) was well-tolerated with no safety signals observed at both low- and high-dose levels
Patient screening for the Phase 2 combination study of high-dose VBI-2601 (BRII-179) and BRII-835 (VIR-2218) initiated March 2021 – first patient first dose anticipated early Q2 2021
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.